The Securities and Exchange Commission and Elon Musk have asked a federal court in Washington, D.C., to approve a settlement resolving claims that Musk failed to timely disclose his purchases of Twitter stock in 2022. The proposed resolution includes a $1.5 million civil penalty and would close one of the more visible disclosure-related enforcement disputes arising from Musk’s acquisition of the social media platform.

At the center of the matter is Section 13(d) of the Securities Exchange Act, which generally requires investors who cross the 5% ownership threshold in a public company to promptly disclose that stake to the market.

As the Supreme Court enters the final stretch of its term, the legal industry is closely watching a cluster of pending decisions that could reshape litigation strategy, regulatory compliance, and constitutional doctrine well beyond June. The current legal news cycle is being driven less by a single blockbuster ruling than by the unusually broad practical impact of the Court’s remaining docket.

The cases drawing the most attention reportedly span administrative authority, civil rights, employment-related disputes, and the scope of federal power.

A federal judge in New York has granted preliminary approval to a revised $38 billion settlement in the long-running interchange-fee litigation against Visa and Mastercard, marking another major milestone in one of the largest antitrust-related civil cases in U.S. history. The case centers on merchant allegations that the card networks and related defendants imposed excessive “swipe fees” and maintained anticompetitive rules that inflated the cost of accepting credit cards.

Preliminary approval is not the end of the road.

The Supreme Court denied certiorari in docket 25-906, but the denial drew added attention because Justice Alito noted a dissent from the Court’s refusal to hear the case.

The Justice Department announced on June 16, 2026, that five men were arrested and charged in federal court in connection with an alleged conspiracy to attack and kill government officials and other attendees at a UFC event hosted at the White House. According to prosecutors, the alleged scheme went well beyond inflammatory rhetoric: the government says it involved coordinated planning, weapons procurement, and activity spanning multiple states.

Even at the charging stage, the case stands out for both the alleged target and the theory of prosecution.

The Supreme Court on June 18 narrowed how the federal government may apply the firearms ban covering “unlawful users” of controlled substances, rejecting a broader theory that could have swept in a wide range of gun owners, including some marijuana users. The ruling is likely to become a significant reference point in Second Amendment litigation because it addresses how closely firearm restrictions must fit the government’s asserted public-safety rationale.

At issue was the federal statute that bars certain drug users from possessing firearms.

OhioHealth has agreed to stop using contract provisions that federal antitrust enforcers said restricted insurers’ ability to guide patients to lower-cost providers, resolving one of two government healthcare competition cases against the system. The settlement is a notable reminder that, even as enforcement priorities shift more broadly in Washington, healthcare remains a sector where regulators continue to scrutinize contracting practices that may limit price competition.

At the center of the dispute were alleged “anti-steering” terms in payer contracts.

The Justice Department’s Antitrust Division has completed its review of Paramount’s proposed acquisition of Warner Bros. and concluded the transaction is not likely to substantially lessen competition. In most deal cycles, that would mark the end of the government review story. Here, it may be the beginning of the litigation story.

According to reports, attorneys general in California, New York, and potentially other states are preparing to challenge the merger anyway.

Tesla Inc. has filed a new inter partes review petition at the Patent Trial and Appeal Board, opening IPR2026-00380 on June 18, 2026.

The Seventh Circuit has entered a final judgment in Appeal No. 25-1963 through a nonprecedential disposition, according to the court’s June 16, 2026 order. While the docket entry itself is brief, the procedural posture is still significant for appellate practitioners: the case has been resolved on the merits in a form that binds the parties but does not create precedential law for future litigants.

In practical terms, a “final judgment filed per nonprecedential disposition” means the court concluded the appeal and issued its decision in an unpublished or nonprecedential format rather than through a published opinion.

The Justice Department’s June 19 release slate underscores a familiar but still accelerating reality for companies and counsel: federal enforcement remains broad, fast-moving, and increasingly coordinated across criminal, civil, and regulatory lines. While the day’s headlines span multiple subject areas, the common thread is the government’s continued use of parallel tools—indictments, guilty pleas, settlements, and public-facing compliance messaging—to shape behavior well beyond the immediate defendants.

For legal professionals, the significance is less about any single announcement than about the pattern.

A federal judge in Virginia has indefinitely blocked a roughly $1.8 billion Justice Department fund designed to compensate alleged victims of “lawfare” and government “weaponization,” stopping what had become one of the more unusual post-settlement funding arrangements tied to litigation involving President Donald Trump.

U.S. District Judge Leonie Brinkema, of the Eastern District of Virginia, concluded that the challenged arrangement raised serious legal concerns, especially around whether the executive branch can effectively create or direct a massive compensation pool without clear congressional authorization.

ResMed Corp. has been named in a new inter partes review, IPR2026-00341, filed on June 12, 2026, before the Patent Trial and Appeal Board. While the newly filed docket entry identifies the proceeding by the company name, practitioners will want to watch closely as the petition develops and the challenged patent, claims at issue, and prior-art combinations come into sharper focus through the institution briefing.

At this stage, the publicly available case caption signals that a patent associated with ResMed’s portfolio is being challenged at the PTAB.

Tesla Inc. is the named petitioner in a newly filed inter partes review, IPR2026-00382, at the Patent Trial and Appeal Board, adding another matter for practitioners tracking high-stakes validity disputes before the USPTO.

In a brief but consequential disposition, the Supreme Court reversed the judgment below and remanded the case for further proceedings. Even without a full merits opinion reproduced here, that procedural outcome alone is significant for litigators: a reversal and remand from the Court typically signals that the lower court applied the wrong legal framework, failed to account for controlling precedent, or resolved an issue prematurely.

At a high level, the Court’s action means the prior judgment cannot stand.